言語を選択

NY-ESO-1

NY-ESO-1 詳細

英語名	Cancer/testis antigen 1	市販薬剤の数	0
治験薬の数	25	ターゲットの別称	CTAG1A more，Autoimmunogenic cancer/testis antigen NY-ESO-1，LAGE2A，CTAG1，CTAG1A，CTAG1B，Cancer/Testis Antigen 1B，Cancer/Testis Antigen 6.1，L Antigen Family Member 2，Cancer/Testis Antigen 1，LAGE-2，LAGE2B，CT6.1，CTAG，ESO1，Cancer Antigen 3，NY-ESO-1，LAGE2，New York Esophageal Squamous Cell Carcinoma 1
研究＆開発段階	Phase 3 Clinical

英語名	Cancer/testis antigen 1
ターゲットの別称	CTAG1A more，Autoimmunogenic cancer/testis antigen NY-ESO-1，LAGE2A，CTAG1，CTAG1A，CTAG1B，Cancer/Testis Antigen 1B，Cancer/Testis Antigen 6.1，L Antigen Family Member 2，Cancer/Testis Antigen 1，LAGE-2，LAGE2B，CT6.1，CTAG，ESO1，Cancer Antigen 3，NY-ESO-1，LAGE2，New York Esophageal Squamous Cell Carcinoma 1
市販薬剤の数	0
治験薬の数	25
研究＆開発段階	Phase 3 Clinical

NY-ESO-1 製品リスト

属性
Cell (1)
製品ライブラリ
オンライン (1)
種
Human (1)
タグ
Tag Free (1)
マーカー
- (1)

製品番号	種	発現システム	製品説明	タンパク質の構造	純度	特性
CHEK-STP114	Human	HEK293	NY-ESO-1 specific TCR-HEK293 cell line

総数量1

NY-ESO-1バックグランド

Cluster of Differentiation 3 (CD3) is a pivotal multimeric T cell co-receptor complex essential for adaptive immune responses. Composed of epsilon (ε), gamma (γ), delta (δ), and zeta (ζ) polypeptide chains forming three distinct dimers (εγ, εδ, ζζ), CD3 non-covalently associates with the T-cell receptor (TCR) to establish the critical TCR/CD3 receptor complex on T cell surfaces. Structurally, CD3 proteins belong to the immunoglobulin superfamily, featuring a transmembrane domain, an N-terminal extracellular region with immunoglobulin-like domains, and cytoplasmic tails embedded with immunoreceptor tyrosine-based activation motifs (ITAMs). These ITAMs are fundamental for initiating signal transduction upon T cell receptor engagement, thereby activating both CD4+ T helper and CD8+ cytotoxic T cells. As a defining marker of the T cell lineage, CD3's central role in T cell activation makes its modulation, via stimulating or blocking antibodies, a promising therapeutic avenue for conditions like organ transplant rejection and autoimmune diseases.

NY-ESO-1分子の別称

NY-ESO-1

治験薬に関する情報

英語名	研究コード	研究開発ステージ	会社	適応症	臨床試験
mipetresgene autoleucel	TBI-1301	Phase 3 Clinical	Takara Bio Inc	Esophageal Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Sarcoma, Synovial; Solid tumours; Urinary Bladder Neoplasms	詳細
TCR Affinity Enhancing Specific T cell Therapy	TAEST-16001	Phase 2 Clinical	Guangzhou Institute Of Respiratory Health, Guangzhou Xiangxue Pharmaceutical Co Ltd	Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Osteosarcoma; Ovarian Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms	詳細
Cancer vaccine NY-ESO-1 (Ludwig Institute/Peking University/Jewim Pharmaceutical)		Phase 2 Clinical	Ludwig Institute For Cancer Research	Liver Neoplasms; Melanoma	詳細
Anti-NY-ESO-1 TCR-T cell theray (Shenzhen BinDeBio)		Phase 2 Clinical	Shenzhen Bindebio Ltd	Carcinoma, Hepatocellular; Esophageal Neoplasms; Glioma; Stomach Neoplasms	詳細
Autologous anti-NY-ESO1 T-cell receptor gene-engineered peripheral blood lymphocytes (Roswell)	CD8-TCR-T cells; NY-ESO-1/CD8/HL AA2.1-19305dp-TCR-T cells	Phase 2 Clinical	Roswell Park Cancer Institute	Neoplasms	詳細
VTP-600	VTP-600	Phase 2 Clinical	Barinthus Biotherapeutics PLC, Ludwig Institute For Cancer Research	Carcinoma, Non-Small-Cell Lung	詳細
NY-ESO-1TCR/dnTGFBRII Engineered T Cells therapy (The University Of Chicago)	NY-ESO-1 TCR/ dnTGFβRII	Phase 2 Clinical	The University Of Chicago	Ovarian Neoplasms; Solid tumours	詳細
NY-ESO-1 TCR/IL-15 NK		Phase 2 Clinical	Replay Holdings LLC, Syena, The University Of Texas MD Anderson Cancer Center	Liposarcoma, Myxoid; Multiple Myeloma; Sarcoma, Synovial	詳細
TC-N201(TCRCure)	TC-N201	Phase 2 Clinical	Tcrcure Biopharma Ltd	Neoplasms; Solid tumours	詳細
HBI-0201-ESO TCRT	HBI-0201-ESO TCRT	Phase 2 Clinical	Hadassah Medical Organization	Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Sarcoma; Sarcoma, Synovial; Triple Negative Breast Neoplasms	詳細
NY-ESO-1 TCR(Kite Pharma)		Phase 2 Clinical	Kite Pharma, National Cancer Institute	Esophageal Neoplasms; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Meningioma; Neoplasm Metastasis; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms	詳細
Letetresgene autoleucel	GSK-3377794; GSK-794	Phase 2 Clinical	Adaptimmune Llc	Carcinoma, Non-Small-Cell Lung; Melanoma; Multiple Myeloma; Neoplasms; Ovarian Neoplasms	詳細
Anti-NY-ESO-1 murine TCR transduced autologous peripheral blood lymphocytes (Albert Einstein College of Medicine/NCI)		Phase 1 Clinical	Albert Einstein College Of Medicine Inc, National Cancer Institute	Neoplasms	詳細
Neldaleucel	MT601; MT-601	Phase 1 Clinical	Marker Therapeutics Inc	Hodgkin Disease; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms	詳細
Super 1 T-cell receptor therapy (Guangzhou FineImmune Biotechnology)		Phase 1 Clinical	Guangzhou Fineimmune Biotechnology	Lung Neoplasms; Melanoma; Sarcoma; Solid tumours	詳細
PeptiCRAd-1	Valo-D102; PeptiCRAd-1	Phase 1 Clinical	Valor Biotherapeutics	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma, Myxoid; Neoplasms; Osteosarcoma; Sarcoma; Sarcoma, Synovial; Skin Melanoma; Triple Negative Breast Neoplasms	詳細
Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 (LauT-1) therapy(Centre Hospitalier Universitaire Vaudois)	LauT-1	Phase 1 Clinical	Centre Hospitalier Universitaire Vaudois	Melanoma; Sarcoma	詳細
DS-2243	DS-2243a; DS-2243	Phase 1 Clinical	Daiichi Sankyo Co Ltd	Sarcoma; Solid tumours	詳細
SY-104	SY-104	Phase 1 Clinical	Replay Holdings LLC	Multiple Myeloma; Sarcoma	詳細
MDG-1015	MDG1015; MDG-1015	Phase 1 Clinical	Medigene Ag	Carcinoma, Ovarian Epithelial; Gastroesophageal Junction Neoplasms; Liposarcoma; Liposarcoma, Myxoid; Ovarian Neoplasms; Sarcoma, Synovial; Soft Tissue Neoplasms; Solid tumours; Stomach Neoplasms	詳細
TCR-T cells（Fujian Province Tumor Hospita）		Phase 1 Clinical	Fujian Cancer Hospital	Solid tumours	詳細
LYL-132	LYL-132; GSK-4427296	Phase 1 Clinical	Lyell Immunopharma Inc	Neoplasms; Solid tumours	詳細
HLA-A*02:01/NY-ESO-1 TCR-T cell therapy (Pregene)		Phase 1 Clinical	Shenzhen Pregene Biopharma Co Ltd	Sarcoma	詳細
anti-NY-ESO-1 TCR T-cell therapy (Shenzhen BinDeBio)		Clinical	Shenzhen Bindebio Ltd	Neoplasms	詳細
NYESOiNT		Clinical	Eutilex	Neoplasms; Ovarian Neoplasms; Sarcoma	詳細